Intracameral @entity16681 gas in the treatment of acute corneal XXXX .

@entity1 @entity4 @entity9042 @entity16681 @entity2687 @entity38096 @entity528 @entity3279 @entity616
PURPOSE: This study is aimed to evaluate the role of 14% nonexpansile concentration of @entity16681 ( @entity38096 ) gas in the management of acute @entity4 in @entity2687 . DESIGN: Retrospective, nonrandomized, comparative, interventional case series. @entity1 AND CONTROLS: The study group consisted of 62 eyes of 57 @entity1 and the control group included 90 eyes of 82 @entity1 with acute corneal @entity4 who presented within 30 days of onset of symptoms. INTERVENTION: @entity1 in the control group underwent a single intracameral injection of 0.1 mL of nonexpansile concentration (14%) of @entity38096 gas. @entity1 in the control group were treated conservatively. @entity1 in both groups were followed regularly for 12.6  7.7 and 13.4  8.3 months in the study and control groups, respectively, and assessed clinically for complete disappearance of epithelial and stromal @entity4 on slit-lamp biomicroscopy. MAIN OUTCOME MEASURES: The primary outcome measure was mean time to resolution of @entity3279 , which was calculated both from the date of onset of @entity4 and the date of initiation of therapy to the date of resolution in days. RESULTS: The overall time to resolution both from the date of onset of symptoms (90.5  55.8 vs 125  68.9 days; P = 0.0005) and from the date of initiation of therapy (78.7  53.2 vs 117.9  68.2 days; P = 0.0001) was significantly lower in the study group compared with the control group. However, on subgroup analysis a significant difference in the resolution time was found only in eyes with @entity9042 (P<0.0001). No difference in the resolution time was seen in eyes with pellucid marginal @entity528 (PMCD) or keratoglobus. The main complication of this procedure was reversible @entity616 (16%; P<0.0001). There was no difference in the final visual acuity or endothelial cell counts between the 2 groups. CONCLUSIONS: Intracameral @entity38096 gas in a nonexpansile concentration is a useful modality for faster resolution of @entity3279 in @entity1 with acute corneal @entity4 and @entity9042 , and its role in the treatment of PMCD and keratoglobus needs further evaluation.
